New drug combo shows promise for tough head and neck cancers
NCT ID NCT02308072
First seen May 24, 2026 · Last updated May 24, 2026
Summary
This early-stage trial tested adding the drug olaparib to standard chemotherapy and radiation for people with high-risk head and neck cancer. The goal was to find the safest dose and see how well patients tolerated the combination. Sixteen adults with advanced disease took part, and researchers monitored side effects closely.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Guy's and St Thomas' NHS Foundation Trust
London, United Kingdom
-
University College London Hospitals NHS Foundation Trust
London, United Kingdom
-
Velindre Cancer Centre
Wales, CF14 2TL, United Kingdom
Conditions
Explore the condition pages connected to this study.